GlassScriptPhysician profile
Samuel Fixler Harris
NPI 1750813895
$4,743.30
in general payments reported to CMS, 2019-2025
43 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.57 · 2020: $265 · 2021: $692 · 2022: $646 · 2023: $365 · 2024: $1,375 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $958.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $639.65 | 2020-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.78 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $309.48 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $268.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $226.50 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $179.04 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $165.47 | 2019-2025 | Farxiga, Airsupra |
| Boston Scientific Corporation | $134.73 | 2025 | Versacross Access Solution, Watchman Flx |
| Exact Sciences Corporation | $128.72 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $102.80 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $100.81 | 2024 | |
| Cvrx, INC. | $92.99 | 2023-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $89.12 | 2024 | Arcalyst |
| Philips North America LLC | $86.29 | 2024 | (Cm9) Amb Mon & Diag Und |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.57 | 2024-2025 | |
| Saluda Medical Americas, INC. | $46.56 | 2025 | Evoke |
| Phathom Pharmaceuticals, INC. | $45.05 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $43.62 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $39.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.19 | 2020-2021 | |
| Baxter Healthcare | $33.07 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Cardiva Medical, INC. | $32.49 | 2023 | Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $32.28 | 2024-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $30.30 | 2024-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $29.82 | 2021-2024 | Contrave |
| Abbott Laboratories | $28.89 | 2025 | Navitor |
| Otsuka America Pharmaceutical, INC. | $26.56 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $25.97 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.31 | 2025 | Caplyta |
| Astellas Pharma US INC | $23.94 | 2022 | |
| Insulet Corporation | $23.04 | 2024 | Omnipod |
| Nalu Medical, INC. | $22.80 | 2023 | Nalu Neurostimulation System |
| Amneal Pharmaceuticals LLC | $22.62 | 2025 | Unithroid |
| Allergan, INC. | $22.32 | 2020 | |
| Abiomed | $21.14 | 2025 | |
| Inspire Medical Systems, INC. | $17.76 | 2025 | Inspire |
| Heartflow, INC. | $17.49 | 2025 | |
| Esperion Therapeutics, INC. | $16.07 | 2024 | Nexletol |
| Hologic Sales and Service, LLC | $15.77 | 2021 | |
| Madrigal Pharmaceuticals | $14.06 | 2025 | Rezdiffra |
| Abbvie INC. | $13.75 | 2025 | |
| Eisai INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.